In children evaluated for a possible macrolide allergy, intradermal testing with a suspected culprit drug at 0.05 mg/mL showed high specificity (92.7%) but limited sensitivity. To confirm an allergy ...

NanoPass Technologies Ltd., a global leader in intradermal delivery solutions, will officially launch MicronJet™ 800 during ...